Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients

Supportive Care in Cancer

Volumn 20, Issue 4, 2012, Pages 877-881

  Driessen, C M L ^a   De Kleine Bolt, K M E ^a   Vingerhoets, A J J M ^b   Mols, F ^b   Vreugdenhil, G ^a  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b TILBURG UNIVERSITY   (Netherlands)

Author keywords

Cancer; Chemotherapy; Neurotoxicity; Oncology; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; OXALIPLATIN; PACLITAXEL; VINBLASTINE; VINCRISTINE;

ADULT; ARM; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED NEUROTOXICITY; COLD INDUCED PARESTHESIA; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DYSESTHESIA; FEMALE; FINE MOTOR FUNCTION; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NETHERLANDS; NEUROPATHY; NEUROTOXICITY; OUTPATIENT DEPARTMENT; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SYMPTOMATOLOGY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; NEUROTOXICITY SYNDROMES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84863480949     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1336-0     Document Type: Article

References (19)

1. Markman M (1996) Chemotherapy-associated neurotoxicity: an important side-effect impacting on quality, rather than quantity of life. J Cancer Res Clin Oncol 122:511-512
2. Calhoun EA, Welshman EE, Chang CH, Lurain LR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynaecologic Oncologic Group- Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741-748
3. Kopec JA, Land SR, Cecchini RS, Ganz PA, Cella D, Costantino JP, Wieand S et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4:W1-W8
4. Almadrones L, Deborah B, Guire M, Walczak J, Colleen M, Tian C (2004) Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology study group. Oncol Nurs Forum 31:615-623
5. Postma TJ, Heimans JJ, Aaronson NK, Grant R, Huddart R, Maher J, Hildehrand JG et al (1999) The impact of chemotherapy induced peripheral neuropathy on quality of life. J Neurol Neurosurg Psychiatry 67:838
6. Verstappen CP, Heimans JJ, Hoekman K (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549-1563
7. Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509-513
8. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17
9. Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21:439-451
10. Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorect Cancer 5:38-46
11. Durand JP, Brezault C, Goldwasser F (2003) Protection against oxaliplatin acute neurosensory toxicity by venlafaxine (effexor). Anti-Cancer Drugs 14:423-425
12. Gamelin L, Bisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5- Fluoroucil and Leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061
13. Mielke S, Mross K, Gerds TA, Schmitdt A, Wasch R, Berger DP, LangeWet al (2003) Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anti Cancer Drugs 14:785-792
14. Screnci D, Mc Keage MJ (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotectieve approaches. J Inorg Biochem 77:105-110
15. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Seminars Oncol 29:21-33
16. Leonard GD, Wright MA, Quinn MG (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116-125
17. Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17:387-393
18. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
19. Oken MM (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655